Abstract A087: Leveraging conformation selectivity of MAPK-targeting inhibitors for tumor-selective targeting of RAS-mutant cancers

作者
Poulikos I. Poulikakos
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:24 (10_Supplement): A087-A087
标识
DOI:10.1158/1535-7163.targ-25-a087
摘要

Abstract The clinical success of small-molecule inhibitors targeting the MAPK pathway critically depends on achieving greater pathway inhibition in tumors than in normal tissues, thereby maintaining a high therapeutic index (TI). Selective BRAF inhibitors (BRAFi) have shown activity in BRAF-mutant tumors, and combinations with MEK inhibitors (MEKi) administered at their maximum tolerated doses (MTD) have been clinically successful. Next-generation pan-RAF inhibitors (panRAFi), developed to target wild-type BRAF and CRAF, have shown activity in RAS-mutant (RAS-MUT) tumors as single agents. However, combining panRAFi with MEKi requires dose reduction of both drugs due to toxicity, resulting in limited clinical benefit. We found that panRAFis preferentially bind activated RAF, showing greater potency in RAS-MUT cells than in normal cells. However, when combined with MEKi, panRAFis drive deep MAPK inhibition in normal cells due to increased binding to the activated, dimeric RAF conformation downstream of RAS activation. This activation is driven by relief of negative feedback from MEK inhibition, explaining the low TI and modest efficacy of panRAFi + MEKi combinations. RAF/MEK glues — small-molecule MEK inhibitors that stabilize the RAF–MEK complex — are currently in clinical development, though their precise mechanism of RAF inactivation has remained unclear. While structural studies have shown these glues bound to both active and inactive RAF conformations, we demonstrate that their inactivating function arises from a biochemical mechanism of spatial trapping: MEK is constitutively cytosolic, and RAF/MEK glues retain RAF in the cytosol, preventing its membrane recruitment and dimerization required for activation. As a result, RAF/MEK glues prevent RAF activation in normal cells and permit full dosing when combined with panRAFi. This combination was better tolerated and led to significantly greater control of RAS-MUT tumors in vivo compared to panRAFi + MEKi. Together, our results provide mechanistic insight and preclinical rationale for the clinical evaluation of RAF/MEK glues in combination with panRAFis in RAS-mutant cancers. They further support a novel paradigm: increasing tumor selectivity by differentially targeting native conformations of non-mutated oncogenic effectors in tumor versus normal cells. Citation Format: Poulikos I. Poulikakos. Leveraging conformation selectivity of MAPK-targeting inhibitors for tumor-selective targeting of RAS-mutant cancers [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2025 Oct 22-26; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2025;24(10 Suppl):Abstract nr A087.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
卿云完成签到 ,获得积分10
刚刚
刚刚
华仔的应助被勒言采纳,获得10
1秒前
1秒前
赘婿的应助被王禹垚采纳,获得10
2秒前
rururu发布了新的文献求助10
2秒前
3秒前
上官若男的应助被lyj采纳,获得10
4秒前
will_li完成签到,获得积分10
4秒前
香蕉觅云的应助被阿盛采纳,获得10
5秒前
田様的应助被孙浩文采纳,获得10
5秒前
5秒前
Tsjng完成签到,获得积分10
5秒前
5秒前
国服躺赢发布了新的文献求助30
6秒前
顺其自然完成签到,获得积分10
7秒前
李瑞程发布了新的文献求助10
7秒前
8秒前
8秒前
松鹤问道完成签到 ,获得积分10
9秒前
9秒前
彩色鸿涛发布了新的文献求助10
10秒前
My_magnum_opus的应助被林夕采纳,获得30
10秒前
jjdgangan完成签到,获得积分10
11秒前
Jio-PPx发布了新的文献求助10
11秒前
heyi1217发布了新的文献求助10
12秒前
12秒前
12秒前
Monster完成签到,获得积分10
12秒前
12秒前
12秒前
QQ完成签到,获得积分10
13秒前
桐桐的应助被合适的吐司采纳,获得10
13秒前
13秒前
13秒前
15秒前
15秒前
16秒前
Jio-PPx完成签到,获得积分10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239